(AGENPARL) – Tue 08 July 2025 Lund, Sweden, 8 July 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA)
today announced that Dr. Richard Philipson has been appointed Chief Medical
Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée Aguiar
-Lucander and be a member of the Executive Committee.
Dr Philipson has over 25 years of industry experience and a successful track
record in drug development, providing clinical leadership resulting in four
product approvals, including in rare disease and gene therapy, and comes with
expertise and success in building high-functioning teams, building pipelines and
executing clinical development programs across all phases of development.  He
also brings in-depth knowledge of regulatory strategy in drug development.  Dr
Philipson most recently was CMO of Calliditas Therapeutics and previously spent
16 years at GlaxoSmithKline (GSK), including four years as Therapeutic Area Head
in the Rare Diseases Unit. He also has experience from Takeda, and a 4-year
period as CMO at Trizell.
“We are very pleased to welcome Dr Philipson to the executive management team as
CMO. He brings invaluable experience in the area of drug development, from first
-in-human to Phase 3, and post-approval studies; with expertise across rare
diseases, inflammation and oncology, which will be critical as we prepare for
the next phase of our development,” said CEO Renée Aguiar-Lucander.
“I am excited to have the opportunity to join Hansa at this stage of the
company’s development. I look forward to working with the Hansa team and
leveraging my experience from prior roles to support upcoming regulatory
submissions and help build a strategic development plan for future indications,”
said Dr Philipson.
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at http://www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3666uihYREcZBt62ZGVeHddSttWPRAzdEgfsY9JJhJx3zLJg9wds2omyNY4a8ZAErT7YKpg54He7uo7RZJ9j9x8kiSqoSpZw1MWgpJom2Eu9Cf.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3666uihYREcZBt62ZGVeHddSttWPRAzdEgfsY9JJhJx3zLJg9wds2omyNY4a8ZAErT7YKpg54He7uo7RZJ9j9x8kiSqoSpZw1MWgpJom2Eu9Cf.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content